-
1دورية أكاديمية
المؤلفون: Verma, Subodh, Mudaliar, Sunder, Greasley, Peter
المصدر: Advances in Therapy. 41(1)
مصطلحات موضوعية: Cardiorenal complications, Cardiorenal protection, Diabetes, SGLT2 inhibitors, SGLT2i mechanisms, Humans, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Renal Insufficiency, Chronic, Glucose, Sodium, Cardiovascular Diseases
الوصف: There is a bidirectional pathophysiological interaction between the heart and the kidneys, and prolonged physiological stress to the heart and/or the kidneys can cause adverse cardiorenal complications, including but not limited to subclinical cardiomyopathy, heart failure and chronic kidney disease. Whilst more common in individuals with Type 2 diabetes, cardiorenal complications also occur in the absence of diabetes. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were initially approved to reduce hyperglycaemia in patients with Type 2 diabetes. Recently, these agents have been shown to significantly improve cardiovascular and renal outcomes in patients with and without Type 2 diabetes, demonstrating a robust reduction in hospitalisation for heart failure and reduced risk of progression of chronic kidney disease, thus gaining approval for use in treatment of heart failure and chronic kidney disease. Numerous potential mechanisms have been proposed to explain the cardiorenal effects of SGLT2i. This review provides a simplified summary of key potential cardiac and renal mechanisms underlying the cardiorenal benefits of SGT2i and explains these mechanisms in the clinical context. Key mechanisms related to the clinical effects of SGLT2i on the heart and kidneys explained in this publication include their impact on (1) tissue oxygen delivery, hypoxia and resultant ischaemic injury, (2) vascular health and function, (3) substrate utilisation and metabolic health and (4) cardiac remodelling. Knowing the mechanisms responsible for SGLT2i-imparted cardiorenal benefits in the clinical outcomes will help healthcare practitioners to identify more patients that can benefit from the use of SGLT2i.
وصف الملف: application/pdf
-
2دورية أكاديمية
المؤلفون: Marc G. Vervloet, Hilda JI de Jong, Jan Pander, Jetty A. Overbeek
المصدر: BMC Nephrology, Vol 24, Iss 1, Pp 1-8 (2023)
مصطلحات موضوعية: Cardiorenal Complications, Chronic Kidney Disease, Diabetes Mellitus, Heart Failure, Prevalence, Diseases of the genitourinary system. Urology, RC870-923
الوصف: Abstract Background Knowledge on prevalence, comorbidities and consequences of chronic kidney disease (CKD) is mandatory to estimate the potential of cardiovascular risk management on a population level. We studied the prevalence of CKD with or without type 2 diabetes mellitus (T2D) and/or heart failure and its cardiorenal complications in The Netherlands. Methods A descriptive cross-sectional and longitudinal cohort study was performed, using data from the Dutch PHARMO Data Network. Prevalence of CKD at a single time point was determined by a recorded diagnosis or by ≥ 2 estimated glomerular filtration rate (eGFR) measurements and urine albumin/creatinine ratio (UACR) that define CKD. A representative group of adults with CKD was included in a longitudinal analysis to study cardiorenal complications. Those were followed until first complication, end of study or death, whichever occurred first. Results The prevalence of CKD was 8.9% in a representative population of 2,187,962 adult Dutch individuals. The average age of persons with CKD was 72 years, 57% were female, 19.9% had T2D, 7.7% heart failure, and 3.0% both T2D and heart failure. In the longitudinal analysis, cerebrovascular events (11/1,000 person-years), hospitalizations for heart failure (10/1,000 person-years), myocardial infarction (5.5/1,000 person-years), and hospitalization for CKD (6.2/1,000 person-years) were the most common first cardiorenal complications. People with CKD with T2D and/or heart failure generally had higher rates of cardiovascular or renal complications or mortality than people with CKD without these comorbidities. Conclusion The prevalence of CKD in The Netherlands is 8.9%. People with T2D or heart failure, or both, in addition to CKD, had numerically higher mortality and cardiorenal complication rates than people without these comorbidities. Optimizing up-to-date cardiovascular risk management in these high-risk individuals may provide health benefits.
وصف الملف: electronic resource
العلاقة: https://doaj.org/toc/1471-2369Test
-
3دورية أكاديمية
المؤلفون: Marc G. Vervloet, Hilda JI de Jong, Jan Pander, Jetty A. Overbeek
مصطلحات موضوعية: Medicine, Sociology, Marine Biology, Cancer, Infectious Diseases, Computational Biology, Information Systems not elsewhere classified, Cardiorenal Complications, Chronic Kidney Disease, Diabetes Mellitus, Heart Failure, Prevalence
الوصف: Supplementary Material 1
الإتاحة: https://doi.org/10.6084/m9.figshare.24558067.v1Test
https://figshare.com/articles/journal_contribution/Additional_file_1_of_Prevalence_of_chronic_kidney_disease_in_the_Netherlands_and_its_cardiovascular_and_renal_complications/24558067Test -
4دورية أكاديمية
المؤلفون: Lydia, Aida, Suastika, Ketut, Martosuwignjo, Pranawa, Sibarani, Roy Panusunan, Nasution, Sally Aman, Sulistijo, Soebagijo Adi
المساهمون: AstraZeneca, Indonesia
المصدر: Acta Medica Indonesiana; Vol 54, No 4 (2022): Acta Medica Indonesiana; 653 ; 23382732 ; 01259326
مصطلحات موضوعية: Type 2 Diabetes Mellitus, SGLT2i, Cardiorenal complications
الوصف: Indonesia ranks seventh with the highest number of cases of type 2 diabetes mellitus (T2DM). T2DM is associated with major undesirable complications including cardiovascular disease and chronic kidney disease. Kidneys play a major role in maintaining glucose homeostasis, leading the development of sodium glucose transporter inhibitors (SGLT2i). These inhibitors block renal sodium and glucose reabsorption. Several cardiovascular trials proved that SGLT2i have cardioprotective and renoprotective roles and have been suggested as a drug of choice in primary and secondary prevention and management of cardiorenal complications associated with T2DM. This review highlights the need for a multidisciplinary recommendation for T2DM management in Indonesian population. Additionally, it is vital to provide the perspective of Indonesian medical experts in terms of screening, diagnosis and treatment as the outcome differs geographically. An expert panel of 6 members from Indonesia was convened to review the existing literature and develop an expert-based review/ summary on this topic. Members were chosen for their proficiency in diabetes, kidney disease and cardiovascular disease. The experts opined that the early use of SGLT2i will be effective in preventing and minimising the progression of cardiorenal complications. Moreover, a consistent multidimensional approach is necessary for improved outcomes.
وصف الملف: application/pdf
العلاقة: https://www.actamedindones.org/index.php/ijim/article/view/2143/pdfTest; https://www.actamedindones.org/index.php/ijim/article/downloadSuppFile/2143/2316Test; https://www.actamedindones.org/index.php/ijim/article/downloadSuppFile/2143/2317Test; https://www.actamedindones.org/index.php/ijim/article/downloadSuppFile/2143/2318Test; https://www.actamedindones.org/index.php/ijim/article/downloadSuppFile/2143/2319Test; https://www.actamedindones.org/index.php/ijim/article/view/2143Test
-
5دورية أكاديمية
المؤلفون: Aida Lydia, Ketut Suastika, Pranawa Martosuwignjo, Roy Panusunan Sibarani, Sally Aman Nasution, Soebagijo Adi Sulistijo
المصدر: Acta Medica Indonesiana, Vol 54, Iss 4 (2022)
مصطلحات موضوعية: type 2 diabetes mellitus, sglt2i, cardiorenal complications, Internal medicine, RC31-1245
الوصف: Indonesia ranks seventh with the highest number of cases of type 2 diabetes mellitus (T2DM). T2DM is associated with major undesirable complications including cardiovascular disease and chronic kidney disease. Kidneys play a major role in maintaining glucose homeostasis, leading the development of sodium glucose transporter inhibitors (SGLT2i). These inhibitors block renal sodium and glucose reabsorption. Several cardiovascular trials proved that SGLT2i have cardioprotective and renoprotective roles and have been suggested as a drug of choice in primary and secondary prevention and management of cardiorenal complications associated with T2DM. This review highlights the need for a multidisciplinary recommendation for T2DM management in Indonesian population. Additionally, it is vital to provide the perspective of Indonesian medical experts in terms of screening, diagnosis and treatment as the outcome differs geographically. An expert panel of 6 members from Indonesia was convened to review the existing literature and develop an expert-based review/ summary on this topic. Members were chosen for their proficiency in diabetes, kidney disease and cardiovascular disease. The experts opined that the early use of SGLT2i will be effective in preventing and minimising the progression of cardiorenal complications. Moreover, a consistent multidimensional approach is necessary for improved outcomes.
وصف الملف: electronic resource
-
6دورية أكاديمية
المؤلفون: S.N. ABDULLAEVA
المصدر: Паёми Сино, Vol 23, Iss 3, Pp 395-409 (2021)
مصطلحات موضوعية: multiple myeloma, cardiorenal complications, diagnostics, free light chains of immunoglobulins, treatment., Public aspects of medicine, RA1-1270
الوصف: A literature review article provides a comprehensive overview of literature related to epidemiology, pathogenesis, diagnosis and treatment of multiple myeloma (MM). Literature data show that MM has unclear patterns of the disease distribution, and there are trends in rising incidence. Although the aetiology of MM is not fully understood, according to most researchers, risk factors (RFs) leading to a progressively high incidence of MM include advanced age, male gender, exposure to harmful environmental factors (ionising radiation, chemical agents), family predisposition, an increased prevalence of autoimmune diseases and obesity. MM is characterised by the absence of specific clinical manifestations and similarity with other conditions, which is one of the factors associated with delay in diagnosis of MM. Damage to internal organs, particularly the heart and kidneys, a frequent complication of MM, leads to mutual burdening and is also one of the factors of adverse outcomes early during the disease. The International Myeloma Working Group (IMWG) diagnostic criteria and additional investigation techniques allow high accuracy to diagnose MM and its complications. Despite the development and introduction of new drugs and treatments, the long-term survival rates in MM patient remains low. Therefore there is a need for further research in this direction.
وصف الملف: electronic resource
-
7
مصطلحات موضوعية: Medicine, Endocrinology, SGLT inhibitors, cardiorenal complications, diabetes, cardiorenal protection, SGLT2i mechanisms, infographic
الوصف: The above infographic represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite).
الإتاحة: https://doi.org/10.6084/m9.figshare.23968659.v2Test
https://figshare.com/articles/media/Potential_underlying_mechanisms_explaining_the_cardiorenal_benefits_of_sodium_glucose_cotransporter_2_inhibitors/23968659Test -
8دورية أكاديمية
المؤلفون: E N Chicherina, A V Padyganova
المصدر: Терапевтический архив, Vol 85, Iss 6, Pp 85-89 (2013)
مصطلحات موضوعية: cardiorenal complications, risk factors, women, Medicine
الوصف: The paper describes the state-of-the-art of risk factors for cardiorenal complications in women. It is shown that while managing women of reproductive, menopausal, and menopausal ages, great importance should be attached to the assessment of all risk factors for the development and progression of chronic renal and cardiovascular diseases. Investigations of the specific features of these factors in women, their enrollment along with men in large-scale randomized trials will serve as a basis for developing more effective programs for the prevention and therapy for cardiovascular and renal diseases and hence will be able to reduce disability rates, to increase quality of life, and to prolong its span.
وصف الملف: electronic resource
-
9دورية أكاديمية
المؤلفون: El-Yazbi, Ahmed F., Elrewiny, Mohamed A., Habib, Hosam M., Eid, Ali H., Elzahhar, Perihan A., Belal, Ahmed S.F.
مصطلحات موضوعية: Thermogenic Modulation of Adipose Depots, Cardiovascular complications of diabetes, Early Cardiorenal Complications, Metabolic Impairment
الوصف: Cardiovascular complications of diabetes and obesity remain a major cause for morbidity and mortality worldwide. Despite significant advances in the pharmacotherapy of metabolic disease, the available approaches do not prevent or slow the progression of complications. Moreover, a majority of patients present with significant vascular involvement at early stages of dysfunction prior to overt metabolic changes. The lack of disease-modifying therapies affects millions of patients globally, causing a massive economic burden due to these complications. Significantly, adipose tissue inflammation was implicated in the pathogenesis ofmetabolic syndrome, diabetes, and obesity. Specifically, perivascular adipose tissue (PVAT) and perirenal adipose tissue (PRAT) depots influence cardiovascular and renal structure and function. Accumulating evidence implicates localized PVAT/PRAT inflammation as the earliest response tometabolic impairment leading to cardiorenal dysfunction. Increasedmitochondrial uncoupling protein 1 (UCP1) expression and function lead to PVAT/PRAT hypoxia and inflammation as well as vascular, cardiac, and renal dysfunction. As UCP1 function remains an undruggable target so far, modulation of the augmented UCP1-mediated PVAT/PRAT thermogenesis constitutes a lucrative target for drug development to mitigate early cardiorenal involvement. This can be achieved either by subtle targeted reduction in UCP-1 expression using innovative proteolysis activating chimericmolecules (PROTACs) or by supplementation with cyclocreatine phosphate, which augments the mitochondrial futile creatine cycling and thus decreases UCP1 activity, enhances the efficiency of oxygen use, and reduces hypoxia. Once developed, thesemolecules will be first-in-class therapeutic tools to directly interferewith and reverse the earliest pathology underlying cardiac, vascular, and renal dysfunction accompanying the earlymetabolic deterioration. ; This work is supported by [Grant 45912] (to A.F.E.-Y.) from the Science, Technology, and Innovation ...
العلاقة: http://dx.doi.org/10.1124/molpharm.123.000704Test; http://hdl.handle.net/10576/50639Test; 187-194; 104
النص الكامل